Genpharm

Related by string. * * Genpharm Inc. *

Related by context. Frequent words. (Click for all words.) 68 Paladin Labs 68 Paladin Labs Inc. 68 Par Pharmaceuticals 66 Alphapharm 65 Elan Pharma 65 gets USFDA nod 64 Mylan Pharmaceuticals Inc. 64 Roxane Laboratories Inc. 63 DRAXIMAGE 63 Biovail Laboratories International 63 Novopharm 63 Generic Version 63 Argatroban 63 #mg #mg [002] 63 Duramed Pharmaceuticals Inc. 63 Aventis Pharmaceuticals 62 ALZA 62 Advicor 62 Penwest Pharmaceuticals 62 Pennsaid R 62 Sanctura 62 Glenmark Generics 62 UCB Pharma 62 Andrx Corporation 61 Grunenthal 61 TAP Pharmaceuticals 61 Barr Laboratories Inc. 61 Interpharm 61 Synthon 61 Ortho McNeil Janssen 61 IntelliPharmaCeutics 61 Esprit Pharma 61 BioVectra 60 Transcept Pharmaceuticals 60 Ondansetron 60 Mission Pharmacal 60 Release Tablets 60 Bayer HealthCare LLC 60 amlodipine besylate 60 FDA Accepts 60 Teva Pharma 60 McNeil PPC Inc. 60 Cilag GmbH International 60 Citalopram 60 Medicis Pharmaceutical Corporation 60 Vicuron Pharmaceuticals 59 GlaxoSmithKline plc GSK 59 Drug Application 59 intravenous formulations 59 Janssen Pharmaceutical 59 Ultram ER 59 Janssen Pharmaceutica NV 59 AMRIX 59 Hydrochloride 59 Axcan Pharma 59 Dimethaid 59 Initiates Phase II 59 Oral Solution 59 Vaccinex 59 ALZA Corporation 59 Drug Submission 59 Kuvan R 59 Ranitidine 59 Roxane Laboratories 59 Inc. Nasdaq MYL 58 Receives Orphan Drug Designation 58 Ethypharm 58 Anika Therapeutics 58 Meda AB 58 Prasco 58 silodosin 58 generic injectable 58 NYSE PRX 58 Company Nasdaq PRGO 58 Par Pharmaceutical Companies 58 Otsuka Pharmaceutical 58 NV Organon 58 Gedeon Richter 58 ANDA containing 58 Upsher Smith 58 Transition Therapeutics 58 Berlex Laboratories 58 Cesamet 58 Mylan Pharmaceuticals 58 Bioniche Pharma 58 Ceftriaxone 58 PhosLo 58 MedPointe 58 Fanapt TM 58 Ethex 58 Novartis Pharma 58 Maxipime 58 Drug Applications ANDAs 58 USFDA approval 58 Portola Pharmaceuticals 57 Xanodyne Pharmaceuticals 57 Ixempra 57 Helsinn 57 Ovation Pharmaceuticals 57 Urokinase 57 inhaled formulation

Back to home page